WASHINGTON, D.C. — A new Medicare pilot program offering broader access to GLP-1 weight-loss medications is generating overwhelming interest from eligible older Americans, with physicians reporting that injectable treatments remain the preferred option despite expectations that pill-based therapies would dominate.

The 18-month pilot, launched by the Centers for Medicare & Medicaid Services (CMS), allows qualifying beneficiaries to access obesity treatments such as Wegovy, Zepbound, and Foundayo at a reduced monthly cost. Healthcare providers say patient demand has exceeded early expectations as obesity management becomes an increasingly important part of preventive healthcare.

Doctors involved in the program report that many patients are choosing injectable medications because of their proven effectiveness in clinical trials. While the rollout has been largely successful, some healthcare providers say administrative approvals and insurance processes remain inconsistent as the program expands nationwide.

Medical experts believe the pilot could provide valuable data on improving access to obesity treatment for older adults while helping reduce long-term risks associated with heart disease, diabetes, and other chronic conditions. If successful, the initiative may influence future Medicare coverage decisions and broader healthcare policy.

Industry analysts are closely watching the program as demand for GLP-1 medicines continues to grow across the United States. The results could shape future investment in obesity care, pharmaceutical innovation, and preventive health strategies over the coming years.